Glimepiride 1 MG +Metformin 500 MG (SR)+Voglibose 0.1 MG Tablets – GLANIL MV1 Tablets

GLANIL MV1 Tablets
Composition:- Glimepiride 1 mg +Metformin 500 mg (SR)+Voglibose 0.1 mg

GLANIL MV1 Tablets – The Triple combination of Glimepiride 1 MG + Metformin 500 MG (SR) + Voglibose 0.1 MG Tablets combines Glimepiride, Voglibose, and Metformin, each with distinct mechanisms to effectively control blood glucose levels in patients with type 2 diabetes mellitus.
Glimepiride, a sulfonylurea, enhances insulin secretion from the pancreas.
Voglibose, an alpha-glucosidase inhibitor, slows carbohydrate absorption in the intestines, specifically helping with postprandial glucose control.
Metformin, a biguanide, improves insulin sensitivity, decreases hepatic glucose production, and enhances peripheral glucose uptake. The extended-release (ER) formulation of Metformin ensures a prolonged, steady effect throughout the day.

Key Points of Glimepiride + Metformin (SR) + Voglibose Tablets – GLANIL MV1 Tablets

• Triple Mechanism of Action – This combination targets three different pathways—pancreatic insulin release, carbohydrate absorption, and insulin sensitivity—for enhanced blood glucose control.
• Comprehensive Glycemic Management – The combination addresses both fasting and postprandial blood glucose, with Voglibose specifically helping to control post-meal spikes.
• Extended-Release Metformin – The ER formulation of Metformin provides sustained blood glucose control with reduced gastrointestinal side effects, allowing once-daily dosing and improved patient adherence.

Can be Prescribed by:

• Endocrinologists
• General Physicians
• Healthcare practitioner

Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.